Skip to main content
SpringerLink
Log in

Continuing clozapine treatment despite neutropenia

  • Review Article
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Rationale

Approximately 1–2% of patients treated with the atypical antipsychotic clozapine develop severe neutropenia and agranulocytosis. The usual recommendation is to discontinue treatment with the drug when the peripheral neutrophil count drops below 1,500/mm3.

Methods

We have reviewed several reports describing procedures that allowed the patients to continue clozapine treatment despite the occurrence of these haematological side effects.

Results

The therapeutic procedures described (symptomatic treatment of neutropenia by co-administration of lithium or granulopoiesis-stimulating factors, management of the adjunctive medication) seem to be efficient strategies that allow continuation of clozapine treatment despite the occurrence of neutropenia. However, these types of therapy have only been used in a limited number of cases, and the evidence supporting their use remains anecdotal.

Conclusion

Although the procedures adopted in the cases described in this review are uncommon, they potentially provide an alternative to the discontinuation of clozapine treatment in patients with complex symptomatologies for whom treatment with other antipsychotic medication is insufficient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Idänpään-Heikkilä J, Alhava E, Olkinuora M, Palva I (1975) Clozapine and agranulocytosis. Lancet 2(7935):611

    Article  Google Scholar 

  2. De la Chapelle A, Kari C, Nurminen M, Hernberg S (1977) Clozapine-induced agranulocytosis. A genetic and epidemiologic study. Hum Genet 37(2):183–194

    Article  PubMed  Google Scholar 

  3. Baldessarini RJ, Frankenburg FR (1991) Clozapine. A novel antipsychotic agent. N Engl J Med 324(11):746–754

    CAS  PubMed  Google Scholar 

  4. Pickar D (1995) Prospects for pharmacotherapy of schizophrenia. Lancet 345(8949):557–562

    Article  CAS  PubMed  Google Scholar 

  5. Lieberman JA (1998) Maximizing clozapine therapy: managing side-effects. J Clin Psychiatry 59(suppl 3):38–43

    Google Scholar 

  6. Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA (1993) Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 329(3):162–167

    Article  CAS  PubMed  Google Scholar 

  7. Hummer M, Kurz M, Barnas C, Fleishhacker W (1992) Transient neutropenia induced by clozapine. Psychopharmacol Bull 28(3):287–290

    CAS  PubMed  Google Scholar 

  8. Lieberman JA, Alvir JMJ (1992) A report of clozapine-induced agranulocytosis in the United States. Incidence and risk factors. Drug Saf 7(suppl 1):1–2

    PubMed  Google Scholar 

  9. Safferman AZ, Lieberman JA, Alvir JMJ, Howard A (1992) Rechallenge in clozapine-induced agranulocytosis. Lancet 339(8804):1296–1297

    Article  CAS  Google Scholar 

  10. Mayfield D, Brown RG (1966) The clinical laboratory and electroencephalographic effects of lithium. J Psychiatr Res 4:207–219

    Article  CAS  Google Scholar 

  11. Murphy DL, Goodwin FK, Bunney WE (1971) Leukocytosis during lithium treatment. Am J Psychiatry 127:1559–1561

    CAS  PubMed  Google Scholar 

  12. Blier P, Slater S, Measham T, Koch M, Wiviott G (1998) Lithium and clozapine-induced neutropenia/agranulocytosis. Int Clin Psychopharmacol 13:137–140

    Google Scholar 

  13. Adityanjee (1995) Modification of clozapine-induced leukopenia and neutropenia with lithium carbonate. Am J Psychiatry 152(4):648–649

    CAS  PubMed  Google Scholar 

  14. Rothstein G, Clarkson DR, Larsen W, Grosser BI, Athens JW (1978) Effect of lithium on neutrophil mass and production. N Engl J Med 298:178–180

    CAS  PubMed  Google Scholar 

  15. Stein RS (1978) Lithium-induced granulocytosis. Ann Int Med 88:809–810

    CAS  Google Scholar 

  16. Barrett AJ (1980) Haematological effects of lithium and its use in the treatment of neutropenia. Blut 40:1–6

    CAS  PubMed  Google Scholar 

  17. Ozdemir MA, Sofuoglu S, Tanrikulu G, Aldanmaz F, Esel E, Dundar S (1994) Lithium-induced hematologic changes in patients with bipolar affective disorder. Biol Psychiatry 35:210–213

    Article  CAS  PubMed  Google Scholar 

  18. Gallicchio VS, Hughes NK (1992) Effective modulation of the haematopoietic toxicity associated with zidovudine exposure to murine and human haematopoietic progenitor stem cells in vitro with lithium chloride. J Int Med 231:219–226

    CAS  Google Scholar 

  19. Sperner-Unterweger B, Gaggl S, Fleischhacker WW, Barnas C, Herold M, Geissler D (1993) Effects of clozapine on hematopoiesis and the cytokine system. Biol Psychiatry 34:536–543

    Article  CAS  PubMed  Google Scholar 

  20. Boshes RA, Manschreck TC, Desrosiers J, Candela S, Hanrahan-Boshes M (2001) Initiation of clozapine therapy in a patient with pre-existing leukopenia: a discussion of the rationale of current treatment options. Ann Clin Psychiatry 13(4):233–237

    Google Scholar 

  21. Sporn A, Gogtay N, Ortiz-Aguayo R, Alfaro C, Tossell J, Lenane M, Gochman P, Rapoport JL (2003) Clozapine-induced neutropenia in children: management with lithium carbonate. J Child Adolesc Psychopharmacol 13(3):401–404

    Article  PubMed  Google Scholar 

  22. Barnas C, Zwierzina H, Hummer J, Sperner-Unterweger B, Stern A, Fleischhacker WW (1992) Granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment of clozapine-induced agranulocytosis: a case report. J Clin Psychiatry 53:245–247

    Google Scholar 

  23. Weide R, Koppler H, Heymanns J, Pfluger KH, Havemann K (1992) Successful treatment of clozapine-induced agranulocytosis with granulocyte-colony stimulating factor (G-CSF). Br J Haematol 80:557–559

    CAS  PubMed  Google Scholar 

  24. Oren R, Granat E, Shtrussberg S, Matzner Y (1993) Clozapine-induced agranulocytosis treated with granulocyte macrophage stimulating factor. Br J Psychiatry 162:686–687

    CAS  PubMed  Google Scholar 

  25. Silverstone PH (1998) Prevention of clozapine-induced neutropenia by pre-treatment with lithium. J Clin Psychopharmacol 18:86–88

    Google Scholar 

  26. Gerson SL, Lieberman JA, Friedenberg WR, Lee D, Marx JJ, Meltzer H (1991) Polypharmacy in fatal clozapine-associated agranulocytosis. Lancet 338:262–263

    Article  CAS  PubMed  Google Scholar 

  27. Valevski A, Modai I, Lahav M, Weitzman A (1993) Clozapine–lithium combined treatment and agranulocytosis. Int Clin Psychopharmacol 8(1):63–65

    Google Scholar 

  28. Jaremin B (1985) Immunoregulatory properties of some heavy metals in physiology and pathology conditions. Bull Inst Marit Trop Gdynia 36:81–88

    CAS  Google Scholar 

  29. Anonymous (2003) Clozaril prescribing information. In: Physicians’ desk reference, 57th edn. Thomson Healthcare, Montvale

  30. Chin-Yee I, Bezchlibnyk-Butler K, Wong L (1996) Use of cytokines in clozapine-induced agranulocytosis. Can J Psychiatry 41:280–284

    CAS  PubMed  Google Scholar 

  31. Nielsen H (1993) Recombinant human granulocyte colony-stimulating factor (fhG-CSF; filgrastim) treatment of clozapine-induced agranulocytosis. J Intern Med 234:529–531

    CAS  PubMed  Google Scholar 

  32. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164–170

    CAS  PubMed  Google Scholar 

  33. Nemunaitis J, Rabinowe SN, Singer JW, Bierman PJ, Vose JM, Freedman AS, Onetto N, Gillis S, Oette D, Gold M (1991) Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 324:1773–1778

    CAS  PubMed  Google Scholar 

  34. Gerson SL, Meltzer HY (1992) Mechanisms of clozapine-induced agranulocytosis. Drug Saf 7(suppl 1):17–25

    PubMed  Google Scholar 

  35. Veys PA, Wilkes S, Shah S, Noyelle R, Hoffbrand AV (1992) Clinical experience of clozapine-induced neutropenia in the UK. Laboratory investigation using liquid culture systems and immunofluorocytometry. Drug Saf 7(suppl 1):26–32

    PubMed  Google Scholar 

  36. Sperner-Unterweger B, Czeipek I, Gaggl S, Geissler D, Spiel G, Fleischhacker WW (1998) Treatment of severe clozapine-induced neutropenia with granulocyte colony-stimulating factor (G-CSF). Br J Psychiatry 172:82–84

    CAS  PubMed  Google Scholar 

  37. Conus P, Nanzer N, Baumann P (2001) An alternative to interruption of treatment in recurrent clozapine-induced severe neutropenia. Br J Psychiatry 179:180

    Article  CAS  PubMed  Google Scholar 

  38. Hägg S, Rosenius S, Spigset O (2003) Long-term combination treatment with clozapine and filgrastim in patients with clozapine-induced agranulocytosis. Int Clin Psychopharmacol 18(3):173–174

    Google Scholar 

  39. Gerson SL (1994) G-CSF and the management of clozapine-induced agranulocytosis. J Clin Psychiatry 55(suppl B):139–142

    Google Scholar 

  40. Palmblad J, Papadaki HA, Eliopoulos G (2001) Acute and chronic neutropenias. What is new? J Intern Med 250:476–480

    Article  CAS  PubMed  Google Scholar 

  41. Balon R, Berchou R (1986) Hematologic side effects of psychotropic drugs. Psychosomatics 27:119–127

    CAS  PubMed  Google Scholar 

  42. Amsler HA, Teerenhori L, Barth E, Hargula K, Vuopio P (1977) Agranulocytosis in patients treated with clozapine—a study of the Finnish epidemic. Acta Psychiatr Scand 56:241–248

    CAS  PubMed  Google Scholar 

  43. Lindström LH (1989) A retrospective study on the long-term efficiency of clozapine in 96 schizophrenic and schizoaffective patients during a 13 year period. Psychopharmacology 99:584–586

    Google Scholar 

  44. Grohmans R, Schmidt LG, Spieb-Kiefer C, Ruther E (1989) Agranulocytosis and significant leucopenia with neuroleptic drugs. Results from the AMUP program. Psychopharmacology 99:109–112

    Article  PubMed  Google Scholar 

  45. Peacock L, Gerlach J (1994) Clozapine treatment in Denmark: concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices. J Clin Psychiatry 55:44–49

    Google Scholar 

  46. Fitton A, Heel RC (1990) Clozapine: a review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 40:722–747

    CAS  PubMed  Google Scholar 

  47. Pantelis C, Adesanya A (2001) Increased risk of neutropenia and agranulocytosis with sodium valproate used adjunctively with clozapine. Aus N Z J Psychiatry 35(4):544–545

    Article  CAS  Google Scholar 

  48. Sénéchal A, Landry P, Deschamps R, Lessard M (2002) Neutropenia in a patient treated with clozapine in combination with other psychotropic drugs. Encephale 28:567–569

    PubMed  Google Scholar 

  49. Pisciotta AV, Konings SA, Ciesemier LL, Cronkite CE, Lieberman JA (1992) On the possible mechanisms and predictability of clozapine-induced agranulocytosis. Drug Saf 7 (suppl 1):33–44

    PubMed  Google Scholar 

  50. Beer D, Cope S, Paton C, Procter A, Wolfson P (1994) Clozapine-induced neutropenia, or not. Br J Psychiatry 164:850

    CAS  Google Scholar 

  51. Meltzer HY, Okayli G (1995) Reduction of suicidality during clozapine treatment of neuroleptic resistant schizophrenia: impact on risk on risk-benefit assessment. Am J Psychiatry 152:183–190

    CAS  PubMed  Google Scholar 

  52. Dickson R, Williams R, Dalby JT (1984) Dystonic reaction and relapse with clozapine discontinuation and risperidone initiation. Can J Psychiatry 39:184

    Google Scholar 

  53. Gerlach J, Koppelhus P, Helweg E, Manrad A (1974) Clozapine and haloperidol in a single-blind cross-over trial. Therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand 50:410–424

    CAS  PubMed  Google Scholar 

  54. Weiden PJ, Olfson M (1995) Cost of relapse in schizophrenia. Schizophr Bull 21:419–429

    CAS  PubMed  Google Scholar 

  55. Krupp P, Barnes P (1989) Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology 99(S, suppl):118–121

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Albert Chenevier Hospital (AP-HP), 40, rue de Mesly, 94000, Créteil, France

    David Esposito, Frédéric Rouillon & Frédéric Limosin

Authors
  1. David Esposito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frédéric Rouillon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Frédéric Limosin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frédéric Limosin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Esposito, D., Rouillon, F. & Limosin, F. Continuing clozapine treatment despite neutropenia. Eur J Clin Pharmacol 60, 759–764 (2005). https://doi.org/10.1007/s00228-004-0835-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-004-0835-z

Keywords

Search

Navigation